Literature DB >> 2647849

The effect of various cytokines on the in vitro induction of antibody-dependent cellular cytotoxicity in murine cells. Enhancement of IL-2-induced antibody-dependent cellular cytotoxicity activity by IL-1 and tumor necrosis factor-alpha.

A Eisenthal1, S A Rosenberg.   

Abstract

We have previously demonstrated that incubation with IL-2 can induce ADCC activity in murine cells and that this activity was mediated by asialo GM1+, FcR+ cells. In the present study we show that the cytokines IFN-alpha and IFN-gamma, TNF-alpha, and IL-1 alpha are unable to induce antibody-dependent cellular cytotoxicity (ADCC) in murine cells; however, TNF-alpha and IL-1 alpha could substantially augment the ADCC induced by IL-2. IL-1 increased the IL-2-induced ADCC activity in a dose-dependent fashion and in cells isolated from the thymus and spleen. The precursors of the ADCC induced by the combination of IL-1 and IL-2 were asialo GM1+ cells, similar to the precursor cells of IL-2-induced ADCC. The effect of IL-1 and TNF on ADCC was not the result of an increase in the FcR density on the cell surface or the result of an increase in the number of FcR+ cells although IL-1 increased the recovery of viable cells in culture. The main effect of IL-1 and TNF was the enhancement of the lytic ability of the IL-2 cultured cells as indicated by increased intra-cellular benzyloxycarbonyl L-lysine thiobenzylester-esterase activity. These results suggest that lymphokines such as IL-1 and TNF may synergize with IL-2 in the induction of ADCC and could thus potentially be useful for the immunotherapy of established tumors when combined with the administration of specific anti-tumor antibodies.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2647849

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  13 in total

1.  Production of tumour necrosis factor by mastocytoma P815 cells.

Authors:  I Ohno; Y Tanno; K Yamauchi; T Takishima
Journal:  Immunology       Date:  1990-02       Impact factor: 7.397

2.  Phenotypic and functional profile of peripheral blood mononuclear cells isolated from melanoma patients undergoing combined immunotherapy and chemotherapy.

Authors:  A Eisenthal; Y Skornick; I Ron; V Zakuth; S Chaitchik
Journal:  Cancer Immunol Immunother       Date:  1993-11       Impact factor: 6.968

3.  Modification of monoclonal antibody carbohydrates by oxidation, conjugation, or deoxymannojirimycin does not interfere with antibody effector functions.

Authors:  M Awwad; P G Strome; S C Gilman; H R Axelrod
Journal:  Cancer Immunol Immunother       Date:  1994-01       Impact factor: 6.968

4.  Effect of allogeneic tumor cells, interleukin-2 and interleukin-6, on the growth of subcutaneous syngeneic tumors.

Authors:  A Eisenthal; Y Skornick; O Merimsky; R Hirsch; V Zakut; I Ron; S Chaitchik
Journal:  Cancer Immunol Immunother       Date:  1993-09       Impact factor: 6.968

5.  Antitumor effects of recombinant interleukin-6 expressed in eukaryotic cells.

Authors:  A Eisenthal; H Kashtan; M Rabau; V Ramakrishna; S Chaitchik; Y Skornick
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

6.  Effect of recombinant human tumor necrosis factor alpha on the induction of antibody-dependent cellular cytotoxicity in the treatment of established B16 melanoma liver nodules.

Authors:  A Eisenthal; J K McIntosh
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

7.  Human recombinant interleukin-6 enhances antibody-dependent cellular cytotoxicity of human tumor cells mediated by human peripheral blood mononuclear cells.

Authors:  K Y Tsang; M D Finch; F J Primus; J Schlom
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

8.  Lung microvascular endothelial cell injury caused by treatment with polymorphonuclear neutrophils and low-IgM serum: a model of transfusion-related acute lung injury.

Authors:  Motoko Nishimura; Minoko Takanashi; Hitoshi Okazaki; Masahiro Satake
Journal:  Lung       Date:  2006 Jan-Feb       Impact factor: 3.777

9.  Comparison of Interleukin-1 Ligand Expression by Human Papilloma Virus Status in HNSCCs.

Authors:  Ishrat Nourin Khan; Katherine N Gibson-Corley; Joseph D Coppock; Andrean L Simons
Journal:  Head Neck Pathol       Date:  2022-03-25

10.  Antitumor effect of recombinant human interleukin-1 beta alone and in combination with natural human tumor necrosis factor-alpha.

Authors:  M Ohkura; S Fuchimoto; K Orita
Journal:  Jpn J Cancer Res       Date:  1990-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.